Fujiwara Tomohiro, Fujiwara Miyuki, Numoto Kunihiko, Ogura Koichi, Yoshida Akihiko, Yonemoto Tsukasa, Suzuki Shigenobu, Kawai Akira
Division of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo.
Division of Ophthalmic Oncology, National Cancer Center Hospital, Tokyo.
Jpn J Clin Oncol. 2015 Dec;45(12):1139-45. doi: 10.1093/jjco/hyv140. Epub 2015 Oct 4.
Second primary malignancies have become the leading cause of death in retinoblastoma survivors. Although osteosarcoma is the most common second malignancy, little is known about its clinical and therapeutic features.
We retrospectively reviewed a database of patients with retinoblastoma and osteosarcoma occurring as a second malignancy between 1964 and 2010 at the National Cancer Center Hospital of Japan.
Among 857 patients with retinoblastoma registered in the database, 10 (1.1%) developed osteosarcoma as a second malignancy. The median age at the onset of retinoblastoma was 3 months, being bilateral in nine patients and unilateral in one. Systemic chemoreduction was performed in three patients and intra-arterial chemotherapy in six; all patients received external beam radiotherapy. The median age at the onset of second primary osteosarcoma was 11.2 years; four were radiation-related and six were located in an extremity. Among five patients treated at our institute, four patients with tumors on an extremity were treated by wide resection with neoadjuvant and adjuvant chemotherapy. Three of these four patients (75%) were good responders to high-dose methotrexate-based multi-agent chemotherapy and survived with no evidence of disease (median follow-up period, 17.3 years). One patient whose temporal bone was affected underwent radiotherapy with chemotherapy but died after local recurrence.
The clinical outcomes of second primary osteosarcoma in an extremity occurring in retinoblastoma survivors may be more favorable than those of conventional osteosarcoma. Early diagnosis of radiation-related osteosarcoma arising in the craniofacial region should be made at a stage where complete resection is possible.
第二原发恶性肿瘤已成为视网膜母细胞瘤幸存者的主要死因。尽管骨肉瘤是最常见的第二原发恶性肿瘤,但其临床和治疗特征却鲜为人知。
我们回顾性分析了1964年至2010年期间日本国立癌症中心医院发生的视网膜母细胞瘤合并骨肉瘤作为第二原发恶性肿瘤患者的数据库。
在数据库中登记的857例视网膜母细胞瘤患者中,有10例(1.1%)发生了骨肉瘤作为第二原发恶性肿瘤。视网膜母细胞瘤发病的中位年龄为3个月,其中9例为双侧,1例为单侧。3例患者接受了全身化疗减瘤,6例接受了动脉内化疗;所有患者均接受了外照射放疗。第二原发骨肉瘤发病的中位年龄为11.2岁;4例与放疗相关,6例位于四肢。在我院治疗的5例患者中,4例四肢肿瘤患者接受了广泛切除并辅以新辅助和辅助化疗。这4例患者中有3例(75%)对以大剂量甲氨蝶呤为基础的多药化疗反应良好,无疾病证据存活(中位随访期,17.3年)。1例颞骨受累的患者接受了放疗和化疗,但在局部复发后死亡。
视网膜母细胞瘤幸存者发生在四肢的第二原发骨肉瘤的临床结局可能比传统骨肉瘤更有利。对于颅面部区域发生的与放疗相关的骨肉瘤,应在能够完全切除的阶段进行早期诊断。